Kai Yu Jen

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

Vivek Subbiah, Vaibhav Sahai, Dejan Maglic et al. · Cancer Discovery · 2023 · 103 citations · Full text

Two‐phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells

Mei Syafriadi, Jun Cheng, Kai Yu Jen et al. · Journal of Oral Pathology and Medicine · 2005 · 30 citations

Parenchymal-stromal switching for extracellular matrix production on invasion of oral squamous cell carcinoma

Hamdy Metwaly, Satoshi Maruyama, Manabu Yamazaki et al. · Human Pathology · 2012 · 24 citations

Tumor Biology, Medicine, Oral Cavity +12

CD45RB Ligation Inhibits Allergic Pulmonary Inflammation by Inducing CTLA4 Transcription

Kai Yu Jen, Monica Campo, Hongzhen He et al. · The Journal of Immunology · 2007 · 22 citations · Full text

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

Alison M. Schram, Suneel D. Kamath, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2021 · 14 citations

Pathology, Cholangiopathies, First-in-human Study +16